Saturday, 12 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

MOPOLI Stock Bearish By 9% So Far Today

Loading stream...

(VIANEWS) - Shares of MOPOLI (BEL 20: MOP.BR) dropped 9.09% to €240.00 at 14:22 EST on Thursday, after five successive sessions in a row of losses. BEL 20 is rising 0.42% to €3,590.13, after four sequential sessions in a row of gains. This seems, at the moment, a somewhat bullish trend exchanging session today.

About MOPOLI

Palmboomen Cultuur Maatschappij Mopoli (Palmeraies De Mopoli) N.V. invests in tropical agro industry projects in Belgium. The company was incorporated in 1912 and is headquartered in Brussels, Belgium. Palmboomen Cultuur Maatschappij Mopoli (Palmeraies De Mopoli) N.V. is a subsidiary of Geselfina SA.

Earnings Per Share

As for profitability, MOPOLI has a trailing twelve months EPS of €3.56.

PE Ratio

MOPOLI has a trailing twelve months price to earnings ratio of 67.42. Meaning, the purchaser of the share is investing €67.42 for every euro of annual earnings.

More news about MOPOLI (MOP.BR).

Categories

stockMarket

Tags

MOP.BRStock PricePrice DownMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStockMOPOLI
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com